SYK

Overview

SYK (Spleen Associated Tyrosine Kinase) encodes a non-receptor tyrosine kinase with a central role in B-cell receptor (BCR) signaling. SYK was identified as a likely driver gene in diffuse large B-cell lymphoma (DLBCL) by clustering and evolutionary conservation analysis, and inhibitors of SYK have demonstrated clinical activity in non-Hodgkin lymphoma (NHL).

Alterations observed in the corpus

  • SYK was identified as a likely driver gene in DLBCL by mutation clustering and cross-species conservation analysis in WES of 55 DLBCL tumors; tyrosine kinase inhibitors targeting SYK have demonstrated clinical activity in NHL PMID:22343534
  • High RPPA expression in the Immune transcriptomic subclass of cutaneous melanoma but NOT prognostic — suggesting T-cell (LCK) rather than B-cell (SYK) signalling drives the survival benefit of the Immune subtype. PMID:26091043

Cancer types (linked)

  • DLBCL: Recurrent mutations identified by WES, supporting SYK as a candidate driver in diffuse large B-cell lymphoma PMID:22343534

Co-occurrence and mutual exclusivity

  • No co-occurrence or mutual exclusivity data in the current corpus.

Therapeutic relevance

  • SYK inhibitors have demonstrated clinical activity in NHL; the identification of recurrent SYK mutations in DLBCL supports SYK as a therapeutic target in B-cell lymphomas PMID:22343534

Open questions

  • The frequency and precise mutation spectrum of SYK in DLBCL requires characterization in larger cohorts.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:26091043

This page was processed by crosslinker on 2026-05-14.